Últimas noticias sobre HCA Healthcare (NYSE:HCA) Bolsa

HCA Healthcare

HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2024, the firm owned and operated 190 hospitals, 124 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.

Analyst Color

Equities

Market Summary

News

Futures

Pre-Market Outlook

Markets

Analyst Ratings

ETFs

ALUR

ISRG

STBX

Los futuros de acciones cayeron tras la decisión del BOJ de subir tasas al 0,5%. Analiza el impacto en los mercados.

Futuros de EE.UU. caen tras aumento de tasas del Banco de Japón: Análisis y previsiones clave

Earnings

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: AXP, BA, VZ, ISRG y HCA.

5 acciones en el foco este viernes: AXP, BA, VZ, ISRG y HCA

HCA Healthcare Inc

HOLDING CO ADMIE IPTO by Holding Co Admie Ipto SA

Holding Co ADMIE (IPTO) SA

Huachen AI Parking Management Technology Holding Co., Ltd. - Ordinary Shares

Huachen AI Parking Management Technology Holding Co Ltd

HALO COLLECTIVE INC by HALO COLLECTIVE INC.

Halo Collective Inc

Health Catalyst Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barclays analyst Dan Levy downgraded the rating for General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) from Overweight to Equal-Weight and lowered the price target from $70 to $40. General Motors shares closed at $45.14 on Monday. <a href="https://www.benzinga.com/quote/GM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Michael Ha downgraded HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) from Outperform to Neutral and cut the price target from $396 to $336. HCA Healthcare shares closed at $340.62 on Monday. <a href="https://www.benzinga.com/quote/HCA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Amy Li downgraded the rating for Ironwood Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) from Buy to Hold and cut the price target from $8 to $0.7. Ironwood Pharmaceuticals shares closed at $0.6479 on Monday. <a href="https://www.benzinga.com/quote/IRWD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jones Trading analyst Catherine Novack downgraded the rating for Rallybio Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) from Buy to Hold. Rallybio shares closed at $0.2702 on Monday. <a href="https://www.benzinga.com/quote/RLYB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Dan Levy downgraded Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) from Overweight to Equal-Weight and cut the price target from $22 to $14. Mobileye Global shares closed at $12.94 on Monday.  <a href="https://www.benzinga.com/quote/MBLY/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying GM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15082139/image-112-1024x587.png" alt="" class="wp-image-872090" style="width:609px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15082139/image-112-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15082139/image-112-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15082139/image-112-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15082139/image-112.png 1085w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44806916/citigroup-bank-of-america-and-3-stocks-to-watch-heading-into-tuesday">Citigroup, Bank Of America And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Trading Ideas

IRWD

MBLY

RLYB

This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Baird analyst Michael Ha downgrades HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) from Outperform to Neutral and lowers the price target from $396 to $336.

Price Target

Baird Downgrades HCA Healthcare to Neutral, Lowers Price Target to $336

Guggenheim analyst Jason Cassorla initiates coverage on HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Neutral rating.

Initiation

Guggenheim Initiates Coverage On HCA Healthcare with Neutral Rating

In the current market session, HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) stock price is at $337.19, after a 0.03% decrease. However, over the past month, the company's stock went up by 6.70%, and in the past year, by 3.74%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1743105619_0.png" alt="Past Year Chart" />

<h3>HCA Healthcare P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 18.19 in the Health Care Providers &amp; Services industry, HCA Healthcare Inc. has a lower P/E ratio of 15.33. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1743105619_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Price Over Earnings Overview: HCA Healthcare

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$24.00</td>
<td>$50.5K</td>
<td>2.0K</td>
<td>2.0K</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$30.00</td>
<td>$60.2K</td>
<td>2.8K</td>
<td>1.6K</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/28/25</td>
<td>$320.00</td>
<td>$473.7K</td>
<td>609</td>
<td>602</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$320.00</td>
<td>$312.3K</td>
<td>43</td>
<td>502</td>
</tr>
<tr>
<td>AKRO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$27.50</td>
<td>$35.0K</td>
<td>2.4K</td>
<td>469</td>
</tr>
<tr>
<td>GERN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$1.00</td>
<td>$33.7K</td>
<td>413</td>
<td>397</td>
</tr>
<tr>
<td>EWTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$30.00</td>
<td>$32.2K</td>
<td>5.4K</td>
<td>332</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$230.00</td>
<td>$53.6K</td>
<td>6.9K</td>
<td>295</td>
</tr>
<tr>
<td>CAH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$130.00</td>
<td>$44.2K</td>
<td>2.6K</td>
<td>188</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$57.50</td>
<td>$64.9K</td>
<td>9.5K</td>
<td>167</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option sweep with neutral sentiment. It expires in 56 day(s) on May 16, 2025. Parties traded 200 contract(s) at a $24.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $50.5K, with a price of $253.0 per contract. There were 2012 open contracts at this strike prior to today, and today 2073 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a put option trade that happens to be bearish, is expiring today. Parties traded 300 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $60.2K, with a price of $201.0 per contract. There were 2865 open contracts at this strike prior to today, and today 1625 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bullish sentiment. It expires in 7 day(s) on March 28, 2025. Parties traded 600 contract(s) at a $320.00 strike. This particular put needed to be split into 57 different trades to become filled. The total cost received by the writing party (or parties) was $473.7K, with a price of $779.0 per contract. There were 609 open contracts at this strike prior to today, and today 602 contract(s) were bought and sold. 
• Regarding HCA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), we observe a put option sweep with bearish sentiment. It expires in 27 day(s) on April 17, 2025. Parties traded 474 contract(s) at a $320.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $312.3K, with a price of $660.0 per contract. There were 43 open contracts at this strike prior to today, and today 502 contract(s) were bought and sold. 
• For AKRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>), we notice a call option trade that happens to be bearish, is expiring today. Parties traded 20 contract(s) at a $27.50 strike. The total cost received by the writing party (or parties) was $35.0K, with a price of $1750.0 per contract. There were 2499 open contracts at this strike prior to today, and today 469 contract(s) were bought and sold. 
• Regarding GERN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>), we observe a call option trade with bearish sentiment. It expires in 210 day(s) on October 17, 2025. Parties traded 397 contract(s) at a $1.00 strike. The total cost received by the writing party (or parties) was $33.7K, with a price of $85.0 per contract. There were 413 open contracts at this strike prior to today, and today 397 contract(s) were bought and sold. 
• Regarding EWTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>), we observe a call option sweep with bullish sentiment. It expires in 27 day(s) on April 17, 2025. Parties traded 104 contract(s) at a $30.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $32.2K, with a price of $310.0 per contract. There were 5479 open contracts at this strike prior to today, and today 332 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option sweep that happens to be bearish, expiring in 91 day(s) on June 20, 2025. This event was a transfer of 198 contract(s) at a $230.00 strike. This particular call needed to be split into 35 different trades to become filled. The total cost received by the writing party (or parties) was $53.6K, with a price of $271.0 per contract. There were 6965 open contracts at this strike prior to today, and today 295 contract(s) were bought and sold. 
• For CAH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>), we notice a call option sweep that happens to be bullish, is expiring today. Parties traded 137 contract(s) at a $130.00 strike. This particular call needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $44.2K, with a price of $325.0 per contract. There were 2600 open contracts at this strike prior to today, and today 188 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a call option sweep with bearish sentiment. It expires in 91 day(s) on June 20, 2025. Parties traded 116 contract(s) at a $57.50 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $64.9K, with a price of $560.0 per contract. There were 9548 open contracts at this strike prior to today, and today 167 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

AKRO

AMGN

EWTX

GERN

VKTX

10 Health Care Stocks Whale Activity In Today's Session

WIIM

ENSG

UHAL

Shares of hospital an healthcare stocks are trading lower amid concerns over Medicaid an Medicare cuts. Additionally, President Trump recently signed an executive order on healthcare price transparency.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Shares of healthcare stocks are trading lower after President Trump signed an executive order on healthcare price transparency.

HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) has outperformed the market over the past 10 years by 5.72% on an annualized basis producing an average annual return of 17.15%. Currently, HCA Healthcare has a market capitalization of $84.87 billion. 
Buying $100 In HCA: If an investor had bought $100 of HCA stock 10 years ago, it would be worth $486.25 today based on a price of $335.07 for HCA at the time of writing.
<h3>HCA Healthcare's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738337414_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

A federal judge in the District of Columbia on Tuesday afternoon temporarily blocked an executive order given by President Donald Trump that imposed a freeze of all federal grants and loans, putting $3 trillion in funding in jeopardy and <a href="https://www.benzinga.com/25/01/43290381/trumps-federal-spending-freeze-puts-3-trillion-in-limbo-threatens-industries-like-clean-energy-defense-healthcare">entire industries on edge.&nbsp;</a>
The Details: According to a New York Times <a href="https://www.nytimes.com/2025/01/28/us/politics/trump-funding-freeze-blocked.html">report</a>, Judge Loren AliKhan blocked the order late Tuesday afternoon in response to a lawsuit filed by Democracy Forward. The lawsuit argued the directive violated the First Amendment and the Administrative Procedures Act governing the issuance of executive orders. 
Judge AliKhan said she will issue a more permanent decision on Feb. 3 
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/01/43106379/trump-reverses-bidens-ai-policies-on-day-1-what-it-means-for-tech-giants-nvidia-amd-alphabet">Trump Reverses Biden&#8217;s AI Policies On Day 1: What It Means For Tech Giants Nvidia, AMD, Alphabet&nbsp;</a>
Skye Perryman, Democracy Forward's president and chief executive, commented on the judge's decision in a statement.&nbsp;
"We are grateful for this administrative stay to allow our clients time to sort through the chaos created by the Trump administration's hasty and ill-advised actions," Perryman said, per the New York Times. 
Trump's directive, issued Monday by the Office of Management and Budget, required federal agencies to halt disbursements while programs were reviewed for alignment with Trump administration policies and was slated to go into effect on Tuesday at 5 p.m. ET.&nbsp;
But, early Tuesday, state Medicaid programs reported the federal reimbursement portals had been locked. State officials said funding for community health centers, food for families, housing assistance, preschools and disaster relief was in limbo.
According to the New York Times, the White House and OMB said on Tuesday afternoon the funding freeze did "not apply across-the-board" and affected programs on D.E.I. efforts and funding for organizations "that undermine the national interest."
Stocks To Watch: It remains unclear exactly which industries could be affected by Trump's order or if the judge will elect to block it permanently on Feb 3.&nbsp;
However, Medicaid funding had reportedly been stopped at least temporarily. HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) and Universal Health Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) stocks fell on Tuesday. 
Large defense contractors like RTX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) and Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) also face a growing degree of uncertainty regarding government funding and contracts.
Green industries including solar energy could also be on the chopping block for federal funding due to Trump administration policies. Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) dropped 12% Tuesday and Sunrun, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) fell 9.2% amid the uncertainty on future policy changes. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/43287988/microsoft-q2-preview">Microsoft Q2 Earnings Preview: Street &#8216;Too Optimistic&#8217; On Near-Term AI Returns?&nbsp;</a></li>
</ul>
Photo: Shutterstock

Government

Regulations

Health Care

Politics

Legal

Movers

General

NOVA

Judge Blocks Trump's Order To Freeze Federal Grant Money

The White House has ordered a temporary freeze on all federal grants and loans, putting $3 trillion in funding under scrutiny and setting the stage for a legal and political showdown over the congressional power of the purse that could heavily impact a <a href="https://www.benzinga.com/markets">wide range of industries.</a>
The directive, issued Monday by the Office of Management and Budget and received by several media outlets, requires all federal agencies to halt disbursements while programs are reviewed for alignment with President Donald Trump's policy priorities.
This includes halting new awards, existing payment and funding for projects until reviewed.
The exact financial impact of the order remains uncertain. Budget experts cited <a href="https://www.washingtonpost.com/business/2025/01/28/trump-spending-freeze-upends-washington-triggering-legal-threats-delays/">by the Washington Post </a>estimate at least tens of billions of dollars are at stake, though the White House directive suggests the total could be significantly higher.
Of the almost $10 trillion spent by the federal government in fiscal 2024, more than $3 trillion was federal financial assistance, Matthew Vaeth, acting director at the OMB, said in the memorandum.
&#8220;Financial assistance should be dedicated to advancing Administration priorities,&#8221; Vaeth said, adding that &#8220;the use of Federal resources to advance Marxist equity, transgenderism, and green new deal social engineering policies is a waste of taxpayer dollars that does not improve the day-to-day lives of those we serve.&#8221;
The White House said that Social Security and Medicare remain untouched. The sweeping pause threatens funding for universities, nonprofits, contractors and private companies that depend on federal assistance.
&#8220;Nothing in this memo should be construed to impact Medicare or Social Security benefits,&#8221; the memo said. 
The immediate focus will be on how agencies handle exemptions. The OMB memo allows federal departments to request case-by-case approvals, which means some funding may still flow, but the process is likely to be slow and politically charged.
Federal agencies have until Feb. 10, 2025, to provide OMB with detailed reports outlining which programs, projects, and activities are affected by the funding pause.
<h3 class="wp-block-heading">Legal, Political Showdown Over Federal Funds </h3>
The move is triggering legal challenges from nonprofits and Democratic-led states.
Within hours of the announcement, lawsuits were filed in federal courts in New York, Illinois and Oregon, arguing that Trump does not have the authority to withhold congressionally approved spending.
Senate Minority Leader Chuck Schumer was among the first to push back, saying Congress-approved investments are legally mandated and asserting the president lacks the authority to override the Impoundment Control Act of 1974, which restricts unilateral executive control over federal funds.
Trump has long argued that the 1974 law is unconstitutional, stating that past presidents had far more discretion over spending before its passage.
<h3 class="wp-block-heading">Which Industries Could Face Trouble?</h3>
Some of the hardest-hit sectors could include clean energy, defense, health care and education, where federal dollars have played a crucial role in driving investment and growth in recent years.
Trump's OMB memo explicitly targeted climate initiatives and green energy programs. Shares of solar and renewable energy companies were among the hardest hit following the federal funding freeze.
The Invesco Solar ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAN#NYSE">TAN</a>) and the Invesco Wilderhill Clean Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBW#NYSE">PBW</a>) fell by 2% and 1.3%, respectively, on Tuesday. 
Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) dropped 12%, Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) fell 9.2% and SolarEdge Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) declined 5%. 
Defense contractors such as Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), RTX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) and Northrop Grumman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) may also see rising uncertainty. While military spending is unlikely to be cut outright, several defense contractors rely on federal grants for research and development. 
The impact on health care remains unclear. While Medicare is shielded, Medicaid funding — which supports hospitals, managed care providers and pharmaceutical companies — could be at risk.
HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) and Universal Health Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) fell by 1% and 1.4%, respectively, while Tenet Healthcare Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) showed resilience Tuesday. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43281252/fed-set-to-signal-no-rush-to-cut-rates-as-wall-street-awaits-policy-clarity">Fed Set To Signal No Rush To Cut Rates As Wall Street Awaits Policy Clarity</a></li>
</ul>
Photo via Shutterstock.

Large Cap

Sector ETFs

Econ #s

SEDG

Trump's Federal Spending Freeze Puts $3 Trillion In Limbo, Threatens Industries Like Clean Energy, Defense, Health Care

RBC Capital analyst Ben Hendrix maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Outperform and lowers the price target from $405 to $384.

RBC Capital Maintains Outperform on HCA Healthcare, Lowers Price Target to $384

B of A Securities analyst Kevin Fischbeck maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Buy and lowers the price target from $380 to $370.

B of A Securities Maintains Buy on HCA Healthcare, Lowers Price Target to $370

HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) reported better-than-expected earnings for its <a href="https://www.benzinga.com/quote/HCA/earnings">fourth quarter on Friday</a>.
The company posted fourth-quarter revenues of $18.29 billion, up 5.7% year-over-year, slightly above the consensus of $18.23 billion. The hospital chain reported adjusted EPS of $6.22, up from $5.90 a year ago, surpassing the consensus of $6.13. 
&#8220;We finished 2024 with strong business fundamentals that were consistent with previous quarters,&#8221; said Sam Hazen, Chief Executive Officer of HCA Healthcare. &#8220;The first half of the current decade, which ended in 2024, proved to be another period of long-term growth for the company and resulted in operational improvements across key performance indicators and greater value for our patients, employees and shareholders. These accomplishments are a testament to the incredible work of our teams, and position us well for the future.&#8221;
HCA Healthcare forecasts 2025 EPS of $24.05-$25.85 versus a consensus of $24.58, with a sales outlook of $72.8 billion-$75.8 billion versus a consensus of $74.76 billion.
The company expects a 2025 net profit of $5.85 billion-$6.29 billion and adjusted EBITDA of $14.30 billion—$15.10 billion. Capital expenditures for 2025, excluding acquisitions, are estimated to be approximately $5.0 billion to $5.2 billion.
HCA Healthcare shares fell 3.8% to close at $313.07 on Friday.
These analysts made changes to their price targets on HCA Healthcare following earnings announcement.
<ul>
<li>Barclays analyst Andrew Mok maintained HCA Healthcare with an Overweight rating and lowered the price target from $392 to $366.</li>
<li>Cantor Fitzgerald analyst Sarah James reiterated HCA Healthcare with an Overweight rating and maintained a $405 price target.</li>
</ul>
Considering buying HCA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="560" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/27090101/image-207-1024x560.png" alt="" class="wp-image-751323" style="width:575px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/27090101/image-207-1024x560.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/27090101/image-207-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/27090101/image-207-768x420.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/27090101/image-207.png 1162w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/markets/25/01/43189390/top-3-materials-stocks-that-may-fall-off-a-cliff-in-january">Top 3 Materials Stocks That May Fall Off A Cliff In January</a></li>
</ul>

These Analysts Revise Their Forecasts On HCA Healthcare Following Q4 Results

Cantor Fitzgerald analyst Sarah James reiterates HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Overweight and maintains $405 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on HCA Healthcare, Maintains $405 Price Target

Barclays analyst Andrew Mok maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Overweight and lowers the price target from $392 to $366.

Barclays Maintains Overweight on HCA Healthcare, Lowers Price Target to $366

Wall Street paused for a breather on Friday, with the S&amp;P 500 index hovering around the flatline at midday trading in New York after a five-day rally that pushed the market to fresh record highs this week. Meanwhile, investor attention shifted to <a href="https://www.benzinga.com/markets/forex">forex and gold markets.</a>
The greenback is experiencing its worst weekly performance since July 2023, as President Donald Trump refrained from imposing new tariffs during his first week and escalated pressure on the Federal Reserve, urging the central bank to lower interest rates. The U.S. dollar index – tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – dropped 0.7% on Friday, extending its weekly decline to 1.7%.
Adding to the dollar's downward momentum, the Bank of Japan raised interest rates by 25 basis points to 0.5%, the highest level since 2008, in a move that broadly met expectations.
Gold capitalized on the dollar's weakness and rising tensions between the president and the central bank, marking another week of strong gains and approaching all-time highs. The bullion, tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), was trading at $2,777 per ounce.
On the macro front, S&amp;P Global reported a slowdown in private sector growth in January, as the services sector faced an unexpected setback, despite manufacturing expanding for the first<a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43195427/us-services-growth-slows-manufacturing-finally-expands-in-january-inflation-was-broad-based-expert-warns"> time in seven months.</a>
A warning came from the University of Michigan's consumer survey, which downwardly revised the January consumer confidence indicator and pointed to increasing trends of households making purchases in advance to avoid potential price hikes <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43197024/consumer-confidence-declines-as-buying-in-advance-trends-grow">linked to tariffs.</a>
In the cryptocurrency market, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) climbed 2.5% following Trump's executive order signed on Thursday, aimed at strengthening U.S. leadership in digital assets. 
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,314.96</td>
<td>0.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,119.65</td>
<td>0.0%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,541.76</td>
<td>-0.1 %</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,861.02</td>
<td>-0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:00 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012425&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) eased 0.1% to $608.89.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;inched 0.1% lower to $444.96.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) slipped 0.4% to $530.73.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) stalled at $229.40.</li>
<li>The&nbsp;Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) outperformed, up 0.9%; the&nbsp;Technology Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 0.4%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
<ul>
<li>American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) fell 2.4% after reporting fourth-quarter results. </li>
<li>Other stocks moving on quarterly results were Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>), up 1.3%, NextEra Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>), up 4%, HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), down 3.2%, First Citizens BancShares Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>), up 3.1%, Ericsson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>), down 14.3%, Intuitive Surgical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), down 3.6%, Texas Instruments Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), down 7.1%, and CSX Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>), down 2.8%. </li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) soared 8.1% after new weight loss drug amycretin showed strong trial results. </li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43198272/us-stocks-hit-dot-com-era-valuations-vs-bonds-why-some-experts-remain-bullish">US Stocks Hit Dot-Com Era Valuations Vs. Bonds: Why Some Experts Remain Bullish</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Mid Cap

Broad U.S. Equity ETFs

Specialty ETFs

Commodities

Forex

Economics

$BTC

SPDR Dow Jones Industrial Average ETF Trust

ERIC

FCNCA

PowerShares DB US Dollar Index Bullish Fund

Stocks Stall, Gold Nears Record Highs As Dollar Faces Worst Week Since July 2023: What's Driving Markets Friday?

HCA Healthcare shares are trading lower after the company issued 2025 EPS guidance of $24.05-$25.85 versus a consensus of $24.58, and sales guidance of $72.80B-$75.80B versus a consensus of $74.76B.

HCA Healthcare Exec Says Patient Volumes In Q4 Were Impacted By Both The Hurricane And A Depressed Respiratory Season

On Friday,&nbsp;HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>)&nbsp;reported fourth-quarter revenues of $18.29 billion, up 5.7% year-over-year, slightly above the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $18.23 billion</a>.
The hospital chain reported adjusted EPS of $6.22, up from $5.90 a year ago, surpassing the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43188066/hca-healthcare-reports-fourth-quarter-2024-results-and-provides-2025-guidance" rel="noreferrer noopener">consensus of $6.13</a>.
In the fourth quarter of 2024, same-facility admissions increased 3% year over year, while same-facility equivalent admissions increased 3.1%.
Same-facility emergency room visits increased by 2.4%, same-facility inpatient surgeries increased by 2.8%, and same-facility outpatient surgeries declined by 1.3%.
Same facility revenue per equivalent admission increased by 2.9%. For the fourth quarter of 2024, adjusted EBITDA totaled $3.71 billion, compared to $3.62 billion a year ago.
During the fourth quarter of 2024, the company incurred additional expenses and experienced loss of revenues estimated at $200 million, or $0.60 per diluted share, associated with Hurricane Helene&#8217;s impact on its North Carolina facilities, as well as from Hurricane Milton, which impacted certain facilities in Florida.
HCA Healthcare&#8217;s board has authorized an additional share repurchase program for up to $10 billion.
HCA declared a quarterly cash dividend of&nbsp;$0.72&nbsp;per share on its common stock, up from the $0.66 dividend&nbsp;paid in December. The dividend will be paid on March 31 to stockholders of record at the close of business on March 17, 2025.
Guidance:&nbsp;HCA Healthcare forecasts 2025 EPS of $24.05-$25.85 versus a consensus of $24.58, with a sales outlook of $72.8 billion-$75.8 billion versus a consensus of $74.76 billion.
The company expects a 2025 net profit of $5.85 billion-$6.29 billion and adjusted EBITDA of $14.30 billion—$15.10 billion.
Capital expenditures for 2025, excluding acquisitions, are estimated to be approximately <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$5.0 billion to $5.2 billion.</a>
Price Action:&nbsp;HCA Healthcare stock is down 0.463% at $323.86&nbsp;at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/43187095/novo-nordisks-weekly-amycretin-delivers-up-to-22-weight-loss-in-study-stock-soars" target="_blank" rel="noreferrer noopener">Novo Nordisk&#8217;s Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars</a></li>
</ul>
Photo: raker/Shutterstock.com.

Guidance

Dividends

Buybacks

HCA Healthcare Q4 Earnings Beat Steet Estimates Despite Hurricane Impact, Announces $10 Billion Share Buyback Program

2025 Guidance
Today, the Company issued the following estimated guidance for 2025:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2025 Guidance Range</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenues</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$72.80 to $75.80 billion</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Income Attributable to HCA Healthcare, Inc.</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$5.85 to $6.29 billion</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$14.30 to $15.10 billion</td>
</tr>
<tr>
<td colspan="1" rowspan="1">EPS (diluted)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$24.05 to $25.85 per diluted share</td>
</tr>
</tbody>
</table>
</figure>
Capital expenditures for 2025, excluding acquisitions, are estimated to be approximately $5.0 to $5.2 billion.

HCA Healthcare Expects 2025 EPS Of $24.05-$25.85 Versus Consensus Of $24.58, With Sales Guidance Of $72.80B-$75.80B Versus Consensus Of $74.76B

Press Releases

49 HCA Healthcare Hospitals Recognized as "America's Best Hospitals" by Healthgrades

HCA Announces Proposed Public Offering of Senior Notes

HCA Healthcare, Inc. to Present at March Healthcare Conferences

HCA Healthcare Recognized as One of the 2025 World's Most Ethical Companies by Ethisphere for the 15th Time

100 HCA Healthcare Hospitals Earn Healthgrades Patient Safety Excellence Award

HCA Healthcare Announces $1.84 Million HCA Healthcare Foundation Grant to United Way

HCA Healthcare Names Monica Cintado as Senior Vice President of Development

HCA Healthcare, Inc. 1st Quarter 2025 Earnings Conference Call

HCA Healthcare Named One of the World's Most Admired Companies by Fortune

Two Large Clinical Trials Find a Highly Effective Method to Select Appropriate Antibiotics for Patients Hospitalized With Abdominal or Skin and Soft Tissue Infection

Comments

HCA Healthcare

Noticias

Últimas noticias sobre HCA Healthcare (NYSE:HCA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL